Hemorrhagic fever-renal syndrome
ORPHA:340DiseaseNot applicableAll ages
Фенотипы (HPO)60
Очень частый (80–99%)8
HP:0001919Acute kidney injury
HP:0001945Fever
HP:0003259Elevated circulating creatinine concentration
HP:0011037Decreased urine output
HP:0012213Decreased glomerular filtration rate
HP:0030005Capillary leak
HP:0032169Severe infection
HP:0100520Oliguria
Частый (30–79%)23
HP:0000093Proteinuria
HP:0000099Glomerulonephritis
HP:0000622Blurred vision
HP:0000967Petechiae
HP:0001262Excessive daytime somnolence
HP:0001324Muscle weakness
HP:0001649Tachycardia
HP:0001873Thrombocytopenia
HP:0001962Palpitations
HP:0001970Tubulointerstitial nephritis
HP:0001974Leukocytosis
HP:0002013Vomiting
HP:0002018Nausea
HP:0002027Abdominal pain
HP:0002315Headache
HP:0002615Hypotension
HP:0003326Myalgia
HP:0003418Back pain
HP:0004325Decreased body weight
HP:0004729Acute tubulointerstitial nephritis
HP:0012378Fatigue
HP:0025143Chills
HP:0030783Increased circulating interleukin 6 concentration
Периодический (5–29%)21
HP:0000713Agitation
HP:0000790Hematuria
HP:0000975Hyperhidrosis
HP:0001289Confusion
HP:0001903Anemia
HP:0002014Diarrhea
HP:0002090Pneumonia
HP:0002094Dyspnea
HP:0002098Respiratory distress
HP:0002153Hyperkalemia
HP:0002202Pleural effusion
HP:0002248Hematemesis
HP:0002905Hyperphosphatemia
HP:0002910Elevated circulating hepatic transaminase concentration
HP:0011896Subconjunctival hemorrhage
HP:0012735Cough
HP:0031273Shock
HP:0031364Ecchymosis
HP:0100519Anuria
HP:0100598Pulmonary edema
HP:0100785Insomnia
Очень редкий (1–4%)8
HP:0000421Epistaxis
HP:0000822Hypertension
HP:0001259Coma
HP:0002170Intracranial hemorrhage
HP:0002249Melena
HP:0002878Respiratory failure
HP:0011029Internal hemorrhage
HP:0012622Chronic kidney disease
Эпидемиология20
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.74 | Europe | Value and class |
| Point prevalence | 1-5 / 10 000 | 37 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.92 | Austria | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.78 | Belgium | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.06 | Bulgaria | Value and class |
| Annual incidence | 1-9 / 100 000 | 2.2 | Croatia | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.08 | Czech Republic | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.36 | Estonia | Value and class |
| Annual incidence | 1-5 / 10 000 | 29.16 | Finland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.18 | France | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.16 | Germany | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.08 | Hungary | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.3 | Latvia | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.44 | Luxembourg | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.02 | Poland | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.02 | Romania | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.24 | Slovakia | Value and class |
| Annual incidence | 1-9 / 100 000 | 2.32 | Slovenia | Value and class |
| Annual incidence | 1-9 / 100 000 | 2.52 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.5 | Norway | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)